Identification and characterization of a novel hepatitis B virus pregenomic RNA encapsidation inhibitor

• Published in: Antiviral research Vol. 175; p. 104709
• Main Authors: Jo, Eunji, Ryu, Dong-Kyun, König, Alexander, Park, Soonju, Cho, Yoojin, Park, Sang-Hyun, Kim, Tae-Hee, Yoon, Seung Kew, Ryu, Wang-Shick, Cechetto, Jonathan, Windisch, Marc P.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2020
• Subjects: Antiviral Agents - chemistry; Antiviral Agents - isolation & purification; Antiviral Agents - pharmacology; Cells, Cultured; Drug Discovery; Encapsidation; Epsilon signal; HEK293 Cells; Hep G2 Cells; Hepatitis B virus; Hepatitis B virus - drug effects; Hepatitis B virus - genetics; Hepatitis B virus - physiology; Hepatocytes - virology; High-throughput drug screening; High-Throughput Screening Assays; Humans; Polymerase; Pregenomic RNA; RNA, Viral - antagonists & inhibitors; RNA, Viral - genetics; Small Molecule Libraries; Virus Assembly - drug effects; Virus Replication - drug effects; Epsilon signal; primary human hepatocytes; (Z)-2-(allylamino)-4-amino-N′-cyanothiazole-5-carboximidamide; high-throughput screening; sodium taurocholate transporting polypeptide; cell culture-derived HBV; dose-response curve; genotype; Polymerase; epsilon; Encapsidation; patient-derived HBV; High-throughput drug screening; Pregenomic RNA; Hepatitis B virus
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/j.antiviral.2020.104709

Currently, therapies to treat chronic hepatitis B (CHB) infection are based on the use of interferon-α or nucleos(t)ide analogs (NAs) to prevent viral DNA synthesis by inhibiting the reverse transcriptase activity of the hepatitis B virus (HBV) polymerase (Pol). However, these therapies are not curative; thus, the development of novel anti-HBV agents is needed. In accordance with this unmet medical need, we devised a new target- and cell-based, high-throughput screening assay to identify novel small molecules that block the initial interaction of the HBV Pol with its replication template the viral pregenomic RNA (pgRNA). We screened approximately 110,000 small molecules for the ability to prevent HBV Pol recognition of the pgRNA 5′ epsilon (ε) stem-loop structure, identifying (Z)-2-(allylamino)-4-amino-N′-cyanothiazole-5-carboximidamide (AACC). Viral nucleocapsid-captured quantitative RT-PCR and Western blot results revealed that AACC significantly decreased encapsidated pgRNA levels and blocked capsid assembly without affecting core protein expression in stable HBV-replicating cells. As a result, both intra- and extracellular accumulation of viral DNA was strongly reduced. AACC treatment of HepG2-sodium taurocholate transporting polypeptide (NTCP) cells and primary human hepatocytes infected with cell culture- or patient-derived HBV isolates showed both time- and dose-dependent inhibition of infectious viral progeny and rcDNA production. Furthermore, AACC showed cross-genotypic activity against genotypes B, C, and D. Of note, AACC inhibited the viral replication of lamivudine and a capsid inhibitor-resistant HBV, and showed synergistic effects with NAs and a capsid inhibitor. In conclusion, we identified a novel class of compounds specifically targeting the ε-Pol interaction and thereby preventing the encapsidation of pgRNAs into viral capsids. This promising new HBV inhibitor class potently inhibits HBV amplification with distinct characteristics from existing NAs and other drugs currently under development, promising to add value to existing therapies for CHB. •Target-based HTS identifies HBV encapsidation inhibitors interfering with the interaction of HBV polymerase and pgRNA.•AACC blocks capsid formation, suppresses viral replication, and has cross-genotypic activity.•AACC inhibits HBV replication of cell culture- and patient-derived HBV in infected HepG2-NTCP cells and PHHs.•AACC inhibits drug-resistant viruses and is synergistic with nucleoside analogs and a capsid inhibitor.